Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is kind of odd:
The IP address of www.bioharpunius.com is 97.74.144.158
The IP address 97.74.144.158 is assigned to Spain
I just looked into my crystal ball....
PR tomorrow at 8 57 stating that the new website is up and KFDA approval should be finalized soon.
“You have your way. I have my way. As for the right way, the correct way, and the only way, it does not exist.”
Friedrich Nietzsche
I'm a Yankees fan :)
That hardly makes sense.
I wholeheartedly believe in XMDC and I am averaging down. By saying it is a great time to buy in, I am doing nothing but promoting this stock and encouraging others to get in at a 'good' price.
It's understandable that the MM's manipulate this stock. But, once we get KFDA approval and the 'average' investor wants a piece we should def. see a nice rise in the PPS, imho.
Dec 15, 2009 08:09:50 (ET)
NEW YORK, Dec 15, 2009 (GlobeNewswire via COMTEX) -- Kohlberg Capital Corporation (KCAP, Trade ) ("Kohlberg Capital") today announced that its Board of Directors has declared a cash dividend of $0.20 per share on shares of its common stock for the quarter ended December 31, 2009. The dividend is payable on January 25, 2010 to shareholders of record as of December 28, 2009.
The cash dividend is comprised of Kohlberg Capital's estimate of net investment income for the quarter ended December 31, 2009 as well as a portion of its estimated undistributed taxable income for the year. Kohlberg Capital estimates that approximately $0.05 to $0.07 per share of additional distributable taxable income for 2009 will be distributed in 2010.
We have adopted a dividend reinvestment plan ("DRIP") that provides for reinvestment of our dividends on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if we declare a cash dividend, our stockholders who have not "opted out" of our dividend reinvestment plan will have their cash dividends automatically reinvested in additional shares of our common stock, rather than receiving the cash dividends. Please contact your broker or other financial intermediary for more information regarding the DRIP.
About Kohlberg Capital Corporation (KCAP):
Kohlberg Capital Corporation is a publicly traded, internally managed business development company. Our middle market investment business originates, structures, finances and manages a portfolio of term loans, mezzanine investments and selected equity securities in middle market companies. Our wholly-owned portfolio company, Katonah Debt Advisors, manages CLO Funds that invest in broadly syndicated corporate term loans, high-yield bonds and other credit instruments. Kohlberg Capital Corporation's filings with the Securities and Exchange Commission, earnings releases, press releases and other financial, operational and governance information are available on Kohlberg Capital's website at www.kohlbergcapital.com .
The Kohlberg Capital logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3121
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Kohlberg Capital Corporation
CONTACT: Kohlberg Capital Corporation
Denise Rodriguez, Investor Relations
(212) 455-8300
info@kohlbergcapital.com
Man, .034 is such a great entry point....
The smiley drinking coffee always makes me want another cup!
not 1.00 - I said .10
.06 will look good when we reach.1 - no?
Last PR:
Kohlberg Capital Corporation Delays Filing of Third Quarter Report on Form 10-Q
NEW YORK, Nov 9, 2009 (GlobeNewswire via COMTEX News Network) -- Kohlberg Capital Corporation (Nasdaq:KCAP) (the "Company") has delayed the release of its full earnings results for the quarter ended September 30, 2009 while it is in discussion with its independent public accountants, Deloitte & Touche LLP ("Deloitte"), regarding valuation determinations under Statement of Financial Accounting Standards No. 157 -- Fair Value Measurements ("SFAS 157") included in its financial statements for the fiscal year ended December 31, 2008 (the "December 31, 2008 financial statements") and for subsequent interim periods in 2009. The Company has been informed by Deloitte that as a result of an annual internal inspection process, certain questions have been raised by Deloitte regarding the Company's methodology and process of valuing its loan portfolio investments under SFAS 157. Deloitte has requested information in addition to that which was previously provided by the Company for purposes of its review. Deloitte issued an unqualified opinion on the December 31, 2008 financial statements, which was included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2009.
Because the Company's financial statements for the quarter ended September 30, 2009 incorporate its balance sheet as of December 31, 2008, the finalization and filing of the Company's quarterly report on Form 10-Q for the third quarter of 2009 will be delayed. Accordingly, the Company will be unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 by today's deadline, and it intends to file a Notification of Late Filing on Form 12b-25 with the Securities and Exchange Commission. The Company is, however, able to report that its net investment income for the nine months ended September 30, 2009 was approximately $17.9 million, or $0.81 per basic and diluted share, and for the three months ended September 30, 2009, net investment income was approximately $4.4 million, or $0.20 per basic and diluted share. The Company's third quarter net investment income of $0.20 per basic and diluted share includes the impact of higher interest costs on its credit facility due to a decision by its lenders to charge default interest, which the Company disputes. The Company estimates that its net investment income would have been approximately $0.29 per basic and diluted share for the quarter ended September 30, 2009 had the interest rate on its credit facility remained at its original stated terms. The Company has declared year-to-date dividends of $0.72 per share, consisting of dividends of $0.24 per share in each of the first, second and third quarters of 2009. The Company expects that in addition to its upcoming regular fourth quarter dividend, a further incremental or special dividend will be declared once the Company has determined the amount of its remaining undistributed taxable income for 2009.
The Company's Quarterly Report on Form 10-Q containing its full earnings results for the quarter ended September 30, 2009 will be filed as soon as practicable.
About Kohlberg Capital Corporation:
Kohlberg Capital Corporation is a publicly traded, internally managed business development company. Our middle market investment business originates, structures, finances and manages a portfolio of term loans, mezzanine investments and selected equity securities in middle market companies. Our wholly-owned portfolio company, Katonah Debt Advisors, manages CLO funds that invest in broadly syndicated corporate term loans, high-yield bonds and other credit instruments.
The Kohlberg Capital logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3121
Kohlberg Capital Corporation's filings with the Securities and Exchange Commission, earnings releases, press releases and other financial, operational and governance information are available on the Company's website at www.kohlbergcapital.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The matters discussed in this press release, as well as in future oral and written statements by management of Kohlberg Capital Corporation, that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. Important assumptions include our ability to originate new investments, and achieve certain margins and levels of profitability, the availability of additional capital, the ability to complete additional CLO funds and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this press release should not be regarded as a representation by us that our plans or objectives will be achieved. Further information about factors that could affect our financial and other results is included in our filings with the Securities and Exchange Commission. We do not undertake to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required to be reported under the rules and regulations of the Securities and Exchange Commission.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities of any CLO fund. Such securities have not been, and will not be, registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Kohlberg Capital Corporation
CONTACT: Kohlberg Capital Corporation
Investor Relations
Denise Rodriguez
(212) 455-8300
info@kohlbergcapital.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX
Any other KCAP's on IHUB?
Q3 earnings are expected to be announced on December 14, 2009Estimates: 0.26 | 0.23 | 0.20 (High | Mean | Low)
Kohlberg Capital Corporation is an internally managed, non-diversified, closed-end investment company. The Company originates, structures and invests in senior secured term loans, mezzanine debt and selected equity securities primarily in privately held middle market companies. In addition to the Company's middle market investment business, its wholly owned portfolio company, Katonah Debt Advisors and its affiliates manage collateralized loan obligation funds (CLO Funds) that invest in syndicated loans, bonds and other corporate credit instruments. As of December 31, 2008, Katonah Debt Advisors had approximately $2.1 billion of assets under management. On January 2, 2008, the Katonah Debt Advisors platform acquired Scott's Cove Capital Management LLC (Scott's Cove), an asset manager focused on an event-driven credit long short investment strategy.
I added 47k today and will be adding 100k on Wednesday. Very excited.
Q1 of 2010 should be interesting, to say the least.
I imagine each country uses it's own Administration to approve devices such as the bio harp.
The Korean Food and Drug Administration (KFDA)
The KFDA oversees the safety and efficacy of drugs and medical devices in Korea. The KFDA is divided into five bureaus, including the Pharmaceutical Safety Bureau and the Medical Device Safety Bureau. These bureaus hold primary responsibility for pharmaceutical and medical device regulatory policy. In addition to its main office in Seoul, the KFDA also has six regional offices that serve as field operational bases.
The KFDA is responsible for nearly every stage in the regulatory process. It establishes safety and quality standards for pharmaceuticals and medical devices, and it oversees the approval process to ensure that new pharmaceuticals and devices conform to their standards. In order to ensure compliance, the KFDA conducts scientific testing on products submitted for approval. For products already on the market, KFDA regional offices carry out post-market surveillance and inspections. The Risk Violation Central Investigation Agency performs criminal investigations and doles out punishments in the event of violations.
In addition to regulatory functions, the KFDA also develops research, study, and analysis methods for pharmaceuticals and medical devices.
*Grammar
Cool, thanks
If/When the 'harp passes KFDA and FDA approval is there a chance a bigger company can come and buy it from XMDC?
And how would this effect us?
Anyone else own some UTSI?
Yea, I am 26 and seem to be handling this much better than people much older.
Investing is gambling, you shouldnt be investing if you cant afford to lose the cash.
How old are you people? Everyone seems very immature. 98% of people here claim to be 'longs' - if this is true, why are you complaining so much about the pps. If you are so long and believe in XMDC, check back in 90 days.
Why did people think they were going to see .20 anyway???? There is no revenue yet. Even if you did see .20, if you are long - you are still holding anyway.
Grow up.
No problem, chief.
Nice English, chief.
Correction, we own the bio harp too.
Found this explanation - easy to understand:
Establishing the monetary size of a corporation is the basis for evaluating a company's overall value. People may just look at the price of a company's stock and think that determines value. Market capitalization is the overall value of a company according to the market
Ascertain the current price of the company's stock. This information is readily available from the company's web site, newspaper, or financial web site.
Step 2Determine the total number of outstanding shares of stock for a company. Again, this information is readily available from the company's web site, newspaper, or financial web site.
Step 3Multiply the total number of shares outstanding by the current share of the company's stock. This number is the company's market capitalization. In essence, it is how much it would cost if a company or individual purchased all shares at the current stock price. For example, if there are 2 million outstanding shares of the company and the current price is 20 dollars, then the market capitalization of said company is 40 million dollars.
Step 4Understand the classification of market capitalization. Small market capitalized stocks or small caps range in value from 300 million to 2 billion dollars. Middle market capitalization stocks or mid caps range in value from 2 billion to 10 billion dollars. Large market capitalization stocks or large caps are stocks with a market capitalization of over ten billion dollars. Mega market capitalization stocks or mega caps are stocks with a market capitalization of over 200 billion dollars
Don't get me wrong- I love making money but I really hope the Bio Harp is as revolutionary as it sounds to be.
Good Luck all.
l2? any sells?
I was is in a conf call and got the google alert for the asset purchase. Guess no buying at .04s tomorrow!
I agree. Good luck to you sir.
Yea, i know its all speculation. Honestly, I expected it today too. I have 250k shares - just wanted to add a bit more. I want the PR to hit and propel us but it would be nice to get more money into this at .045 range
I have 5,000 waiting to clear in my zecco account. It will ready to invest on Friday mornin' Think I will be buying 4's?
I'm trying to pick up 40K at .044 before the bell - hope it goes through
You should learn to read and write before you start predicting stock.